347 related articles for article (PubMed ID: 34059198)
1. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F; Pecci A; Balduini CL
J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
[TBL] [Abstract][Full Text] [Related]
3. Platelet enhancement by Carica papaya L. leaf fractions in cyclophosphamide induced thrombocytopenic rats is due to elevated expression of CD110 receptor on megakaryocytes.
Nandini C; Madhunapantula SV; Bovilla VR; Ali M; Mruthunjaya K; Santhepete MN; Jayashree K
J Ethnopharmacol; 2021 Jul; 275():114074. PubMed ID: 33831466
[TBL] [Abstract][Full Text] [Related]
4. Molecular insights on Eltrombopag: potential mitogen stimulants, angiogenesis, and therapeutic radioprotectant through TPO-R activation.
Subbarayan R; Srinivasan D; Shadula Osmania S; Murugan Girija D; Ikhlas S; Srivastav N; Balakrishnan R; Shrestha R; Chauhan A
Platelets; 2024 Dec; 35(1):2359028. PubMed ID: 38832545
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
Townsley DM; Desmond R; Dunbar CE; Young NS
Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
[TBL] [Abstract][Full Text] [Related]
6. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling.
Lebois M; Dowling MR; Gangatirkar P; Hodgkin PD; Kile BT; Alexander WS; Josefsson EC
J Thromb Haemost; 2016 Sep; 14(9):1882-7. PubMed ID: 27344013
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M
Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796
[TBL] [Abstract][Full Text] [Related]
8. Manipulating megakaryocytes to manufacture platelets ex vivo.
Karagiannis P; Eto K
J Thromb Haemost; 2015 Jun; 13 Suppl 1(Suppl 1):S47-53. PubMed ID: 26149050
[TBL] [Abstract][Full Text] [Related]
9. The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control.
Malara A; Abbonante V; Di Buduo CA; Tozzi L; Currao M; Balduini A
Cell Mol Life Sci; 2015 Apr; 72(8):1517-36. PubMed ID: 25572292
[TBL] [Abstract][Full Text] [Related]
10. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies.
Di Buduo CA; Wray LS; Tozzi L; Malara A; Chen Y; Ghezzi CE; Smoot D; Sfara C; Antonelli A; Spedden E; Bruni G; Staii C; De Marco L; Magnani M; Kaplan DL; Balduini A
Blood; 2015 Apr; 125(14):2254-64. PubMed ID: 25575540
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
[TBL] [Abstract][Full Text] [Related]
12. Lung as a Niche for Hematopoietic Progenitors.
Borges I; Sena I; Azevedo P; Andreotti J; Almeida V; Paiva A; Santos G; Guerra D; Prazeres P; Mesquita LL; Silva LSB; Leonel C; Mintz A; Birbrair A
Stem Cell Rev Rep; 2017 Oct; 13(5):567-574. PubMed ID: 28669077
[TBL] [Abstract][Full Text] [Related]
13. Analysis of clinical characteristics and treatment efficacy in two pediatric cases of
Pang C; Wu X; Nikuze L; Wei H
Platelets; 2023 Dec; 34(1):2262607. PubMed ID: 37852929
[No Abstract] [Full Text] [Related]
14. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation.
Wang D; Lang T; Zeng H; Zou Z; Yang S; Cheng T; Liu H; Zhu L; Xiang X; Yao H; Tang S; Kong P; Wei J; Xiong J; Gao L; Zhang X; Feng Y
Transpl Immunol; 2023 Dec; 81():101948. PubMed ID: 37923019
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cell-Derived Megakaryocytes and Platelets for Disease Modeling and Future Clinical Applications.
Borst S; Sim X; Poncz M; French DL; Gadue P
Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):2007-2013. PubMed ID: 28982668
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey.
Kaushansky K
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672505
[TBL] [Abstract][Full Text] [Related]
18. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
[TBL] [Abstract][Full Text] [Related]
19. Platelet production from induced pluripotent stem cells.
Sugimoto N; Eto K
J Thromb Haemost; 2017 Sep; 15(9):1717-1727. PubMed ID: 28752663
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
